(upper)
500,883 results
  • C2 vs C3 as the Upper Instrumented Vertebra in Posterior Cervical Fusion: Effects on Junctional Mechanics and Midterm Outcomes. [Journal Article]
    Int J Spine Surg. 2026 Aug 28. [Online ahead of print]Shehniamirkhan M, Paeenmahali A, … Alikhani PIJ
  • CONCLUSIONS: Termination at C2 reduces proximal junctional complications and results in a smaller transition angle without compromising midterm clinical outcomes; however, it involves greater operative burden. UIV selection should be individualized, favoring C2 when anatomical feasibility and junctional risk profiles support cranial fixation. Longer-term prospective studies are needed to determine whether mechanical advantages translate into durable clinical benefit.
  • The Burden of Airway Disease in Mucopolysaccharidoses: Evidence Across Subtypes. [Review]
    Laryngoscope. 2026 Aug 28. [Online ahead of print]Edward J, Pincivy A, Bergeron ML
  • CONCLUSIONS: Airway disease in MPS is common, multilevel, and clinically consequential, with substantial burdens of OSA and progressive laryngotracheal pathology. Early, systematic, longitudinal airway assessment is essential to guide counseling and management across MPS subtypes.
  • Therapeutic Efficacy of Co-administered WJ-MSCs and Exosomes in a Rat Pulmonary Fibrosis Model. [Journal Article]
    In Vivo. 2026; 40(5):2717-2725.Choi SH, Baek HJ, … Son WV
  • CONCLUSIONS: Co-administration of WJ-MSCs and their derived exosomes produced substantially greater anti-fibrotic effects than either treatment alone. These preliminary findings suggest exosomes prime the fibrotic microenvironment to enhance WJ-MSC engraftment, with additive paracrine contributions driving superior efficacy. As a single fixed dose at the upper range of previously validated doses was used due to limited animal numbers, future studies with dose-response designs, molecular marker analysis, and functional assessments are warranted.
  • Plexiform Fibrohistiocytic Tumor: An Updated Review. [Review]
    In Vivo. 2026; 40(5):2596-2603.Nishio J, Koga K, Aoki MV
  • Plexiform fibrohistiocytic tumor (PFHT) is a rare locally aggressive and rarely metastasizing mesenchymal neoplasm that most commonly arises in the upper extremities of children and young adults. It typically presents as a small, slow-growing, painless, dermal or subcutaneous mass. Magnetic resonance imaging (MRI) often reveals a plaque-like or infiltrative lesion with intermediate signal intensi…
  • Health-system burden of higher-risk myelodysplastic syndromes in England: a literature-based micro-cost analysis. [Journal Article]
    BMJ Open. 2026 Aug 28; 16(8):e119858.Williamson J, Searle EJ, … Gc VSBO
  • CONCLUSIONS: The direct NHS-provider cost burden of this non-curative HR-MDS management pathway is concentrated in azacitidine acquisition and administration during active treatment, transfusions and admissions after HMA failure and setting-dependent costs at the end of life. The total cost for the illustrative management pathway followed by a patient with HR-MDS (£146 921) is of a similar order to the estimate in the National Institute for Health and Care Excellence technology appraisal for azacitidine uprated to £124 848 for 2024/2025. This comparison is provided for context only and should not be interpreted as validation of the present model, given differences in population, model structure, treatment duration and price year. The phase-specific PPPM estimates can inform, subject to local validation and scenario testing, UK budget-impact analyses, service planning and future economic models.